Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...129130131132133134135136137138139...10651066»
  • ||||||||||  dexamethasone / Generic mfg., epinephrine / Generic mfg.
    Challenging Intubation of Tracheal Stenosis (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_4874;    
    Before subsequent attempts, the patient was given dexamethasone, helium, racemic epinephrine to assist breathing and abate swelling. Four hours later, a repeat attempt at awake fiberoptic in the operating room was successful with a 6.0 millimeter endotracheal tube.
  • ||||||||||  prednisone / Generic mfg., hydrocortisone / Generic mfg., epinephrine / Generic mfg.
    Anamnestic Anaphylactic Arrest After Iodinated Contrast Media (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_4638;    
    Post-extubation, fistulogram was uneventfully performed within a week after pre-medication with oral prednisone. This case highlights that anamnestic anaphylaxis with ICM can happen warranting immediate resuscitation.
  • ||||||||||  Sustained Intraoperative Allergic Reaction to Chlorhexidine (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_4439;    
    Despite appropriate doses of dexamethasone, diphenhydramine, and epinephrine, he remained unresponsive...Only after aborting the case, safely returning the bowels to the abdomen, and washing the offending agent with alcohol from the skin did the patient properly respond to treatment. Postoperative allergy testing was positive for chlorhexidine, confirming anaphylaxis.
  • ||||||||||  Anesthetic Considerations and Management in Brugada Syndrome (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_4262;    
    Post-operative analgesia was comprised of hydrocodone while ondansetron and dexamethasone served as anti-emetics. The operation lasted 210 minutes and no adverse events occurred during the perioperative period.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Retropharyngeal Dissection During Nasotracheal Intubation (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_4205;    
    It was immediately removed with successful placement of a smaller Parker flex tip tube through the other nare. The patient remained intubated in the ICU and received ampicillin-sulbactam and decadron but was unable to be weaned from the ventilator and required subsequent tracheostomy.
  • ||||||||||  Hereditary Angioedema Type III - Preparing for Unknown Perioperative Triggers (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_4199;    
    IV Clindamycin was administered following intubation due to risk of angioedema crisis causing airway swelling. We offer reflections on managing patients with angioedema perioperatively in order to ensure safe airway management.
  • ||||||||||  Elitek (rasburicase) / Sanofi
    Perioperative Management of Chronic Lymphocytic Leukemia (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_4177;    
    Prophylactic lovenox was administered. No complications occurred intra-operatively and patient was eventually discharged to a skill nursing facility with oncology follow-up.
  • ||||||||||  atenolol / Generic mfg., hydrocortisone / Generic mfg.
    A Case Report of Thyroid Storm During Dilation and Curettage of a Patient with Molar Pregnancy (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_4128;    
    Upon extubation, she was hypotensive and bradycardic, requiring blood products and crystalloid for hemodynamic stabilization. This case highlights the importance of early recognition and treatment of thyrotoxicosis in anesthetic management of gynecologic patients.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Journal:  Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. (Pubmed Central) -  Aug 23, 2023   
    Furthermore, comparative studies evaluating this triplet against both doublets and other triplet regimens have established RVd as a standard of care in this setting based upon its remarkable and concordant efficacy. Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of NDMM therapy, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM.
  • ||||||||||  methylprednisolone oral / Generic mfg., dexamethasone injection / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Steroid Administration for Articular Fractures of the Elbow (SAFE Trial) (clinicaltrials.gov) -  Aug 23, 2023   
    P4,  N=2, Terminated, 
    Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of NDMM therapy, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM. N=144 --> 2 | Trial completion date: Apr 2025 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Mar 2023; Switched to observational study type.
  • ||||||||||  Exparel (bupivacaine liposome injectable suspension) / Pacira
    New P4 trial:  Exparel vs Block for ACL Reconstruction (clinicaltrials.gov) -  Aug 23, 2023   
    P4,  N=154, Enrolling by invitation, 
  • ||||||||||  Metopirone (metyrapone) / HRA Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Gluco-Feed: Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals (clinicaltrials.gov) -  Aug 23, 2023   
    P1,  N=20, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | Trial completion date: Feb 2023 --> Jun 2023 | Trial primary completion date: Feb 2023 --> Jun 2023
  • ||||||||||  dexamethasone / Generic mfg.
    Intensity-Modulated Radiotherapy (IMRT) for the Treatment of Cushings Disease (Hall B2; In Person Only; Screen: 20) -  Aug 22, 2023 - Abstract #ASTRO2023ASTRO_702;    
    IMRT was a highly effective second-line therapy with low side effect profile for CD patients. Endocrine remission, tumor control and recurrence rates were comparable to previous reports on FRT and SRS.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal, IO biomarker:  The effects of the differentiated macrophages by dexamethasone on the immune responses. (Pubmed Central) -  Aug 22, 2023   
    Additionally, there was a significant difference in the expression of cytokine genes and M2 differentiation markers among the groups that were evaluated. The effects of Dex on the viability and differentiation of monocytes depend on the dosage, timing, and duration of the treatment.
  • ||||||||||  Corifact (human coagulation factor XIII) / CSL Behring
    Journal:  A case of (Pubmed Central) -  Aug 22, 2023   
    The effects of Dex on the viability and differentiation of monocytes depend on the dosage, timing, and duration of the treatment. Emergency transcatheter arterial embolisation was performed and coagulation factor XIII concentrates (Fibrogammin P
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Systematic review of the long-term effects of postnatal corticosteroids. (Pubmed Central) -  Aug 22, 2023   
    Postnatal dexamethasone exposure has a negative influence on pulmonary and cognitive outcomes in childhood and adolescence. Medications with a better benefit to risk profile need to be identified.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Journal:  Circulating miR-146a predicts glucocorticoid response in thyroid eye disease. (Pubmed Central) -  Aug 22, 2023   
    This is the first study investigating the role of pre-treatment circulating miR-21 and miR-146a to predict responsiveness to GC in TED. miR-146a emerged as a simple, objective, new marker of GC sensitivity that could be used to avoid ineffective administration of GC therapy to TED patients.
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
    Enrollment open, Trial initiation date:  Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant as PONV Prevention (clinicaltrials.gov) -  Aug 22, 2023   
    P=N/A,  N=144, Enrolling by invitation, 
    Trial completion date: Apr 2023 --> Apr 2024 Not yet recruiting --> Enrolling by invitation | Initiation date: May 2023 --> Aug 2023
  • ||||||||||  dexamethasone injection / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  SFSS: Spinal Fusions Steroid Study (clinicaltrials.gov) -  Aug 22, 2023   
    P1,  N=70, Enrolling by invitation, 
    Not yet recruiting --> Enrolling by invitation | Initiation date: May 2023 --> Aug 2023 Not yet recruiting --> Enrolling by invitation | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jan 2025
  • ||||||||||  AO-176 / Arch Oncology
    Trial completion, Enrollment change, Trial completion date, Combination therapy, Monotherapy:  Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) -  Aug 22, 2023   
    P1/2,  N=10, Completed, 
    Not yet recruiting --> Enrolling by invitation | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jan 2025 Active, not recruiting --> Completed | N=157 --> 10 | Trial completion date: Mar 2024 --> Nov 2022
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Effects of pharmacological doses of niacin on subacute glucocorticoid-induced testicular damage in rats. (Pubmed Central) -  Aug 21, 2023   
    Niacin reduced apoptosis as shown by TUNEL assay. In conclusion, niacin administration at pharmacological doses dose-dependently ameliorates the destructive effects of dexamethasone on sperm motility, Johnsen score, and testicular cell apoptosis in rats with the latter can be considered a decisive mechanism for its positive effects on testis.
  • ||||||||||  dexamethasone / Generic mfg., morphine sulphate / Generic mfg.
    Journal, Surgery:  Ultrasound-guided anterior suprascapular nerve block versus interscalene brachial plexus block for arthroscopic shoulder surgery: A randomised controlled study. (Pubmed Central) -  Aug 21, 2023   
    The primary objective was to compare the duration of analgesia (time to first rescue analgesia), and secondary objectives were to compare 24-h postoperative numerical rating scale (NRS) scores, 24-h morphine consumption and post block change in HDE, and pulmonary function tests (PFTs) between the two groups...Pulmonary function was better preserved in the SSB-A group. Compared to ISB, SSB-A has a similar analgesic efficacy for arthroscopic shoulder surgeries, but it is superior in preserving diaphragmatic function and pulmonary function.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Review, Journal:  Selinexor: Targeting a novel pathway in multiple myeloma. (Pubmed Central) -  Aug 21, 2023   
    Based on a clinical trial programme encompassing multiple combination regimens, selinexor-based therapy has been approved for the treatment of relapsed/refractory MM (RRMM), with selinexor-dexamethasone approved in the later-relapse setting for penta-refractory patients and selinexor-bortezomib-dexamethasone approved for patients who have received ?1 prior therapy. Here, we provide a comprehensive review of the clinical data on selinexor-based regimens, including recent updates from the 2022 American Society of Hematology annual meeting, and summarise ongoing studies of this novel targeted agent in newly diagnosed MM and RRMM.
  • ||||||||||  PT150 / The Pop Test & Palisades Therap
    Trial completion date, Trial primary completion date:  Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study) (clinicaltrials.gov) -  Aug 21, 2023   
    P1,  N=10, Recruiting, 
    Trial completion date: Jun 2028 --> May 2027 Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2023 --> Oct 2023
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (clinicaltrials.gov) -  Aug 21, 2023   
    P2,  N=160, Active, not recruiting, 
    Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Jun 2023 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Ninlaro (ixazomib) / Takeda, Opdivo (nivolumab) / BMS
    Enrollment change, Trial termination, Combination therapy:  Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma (clinicaltrials.gov) -  Aug 21, 2023   
    P2,  N=2, Terminated, 
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 N=50 --> 2 | Active, not recruiting --> Terminated; Study closure initiated by industry funding sponsor for commercial reasons.